MRSN vs. SGMO

Last updated Apr 2, 2026

Compare and contrast key facts about Mersana Therapeutics, Inc. (MRSN) and Sangamo Therapeutics, Inc. (SGMO).

Performance

MRSN vs. SGMO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Mersana Therapeutics, Inc. (MRSN) and Sangamo Therapeutics, Inc. (SGMO). The values are adjusted to include any dividend payments, if applicable.

MRSN vs. SGMO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
MRSN Mersana Therapeutics, Inc.	0.52%	-19.08%	-38.36%	-60.41%	-5.79%	-76.63%	364.40%	40.44%	-75.17%	17.36%
SGMO Sangamo Therapeutics, Inc.	-38.07%	-58.82%	87.74%	-82.70%	-58.13%	-51.94%	86.44%	-27.09%	-30.00%	81.22%

Fundamentals

Market Cap MRSN : $145.02M SGMO : $87.84M
EPS MRSN : -$14.05 SGMO : -$0.41
PS Ratio MRSN : 4.37 SGMO : 1.97
Total Revenue (TTM) MRSN : $33.18M SGMO : $39.55M
Gross Profit (TTM) MRSN : $32.89M SGMO : $25.32M
EBITDA (TTM) MRSN : -$66.25M SGMO : -$117.16M

Returns By Period

MRSN

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

SGMO

• 1D: 5.35%
• 1M: -39.50%
• YTD: -38.07%
• 6M: -61.44%
• 1Y: -54.38%
• 3Y*: -47.13%
• 5Y*: -53.74%
• 10Y*: -27.19%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

MRSN vs. SGMO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SGMO

SGMO Risk / Return Rank: 16
SGMO Sharpe Ratio Rank: 18
SGMO Sortino Ratio Rank: 23
SGMO Omega Ratio Rank: 23
SGMO Calmar Ratio Rank: 9
SGMO Martin Ratio Rank: 8

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MRSN vs. SGMO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Mersana Therapeutics, Inc. (MRSN) and Sangamo Therapeutics, Inc. (SGMO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	MRSN	SGMO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	-0.51	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.51	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.29	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	-0.16	—

Correlation

The correlation between MRSN and SGMO is 0.36, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

MRSN vs. SGMO - Dividend Comparison

Neither MRSN nor SGMO has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

Drawdown Indicators

	MRSN	SGMO	Difference
Max Drawdown Largest peak-to-trough decline	—	-99.50%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-69.70%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-98.05%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-99.06%	—
Current Drawdown Current decline from peak	—	-99.48%	—
Average Drawdown Average peak-to-trough decline	—	-83.93%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	39.13%	—

Volatility

Volatility by Period

	MRSN	SGMO	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	28.34%	—
Volatility (6M) Calculated over the trailing 6-month period	—	78.81%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	108.44%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	106.51%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	95.01%	—

Financials